Table 2.
Baseline tumor characteristics stratified by menopausal status
| Pre-menopause (n = 173) | Post-menopause (n = 258) | P value | |
|---|---|---|---|
| Tumor size | |||
| Mean ± SD | 21.6 ± 14.4 | 20.7 ± 11.8 | 0.862 |
| <2 cm | 93 (54.4) | 136 (52.9) | 0.766 |
| ≥2 cm | 78 (45.6) | 121 (47.1) | |
| Nodal status, n (%) | 0.073 | ||
| Negative | 87 (50.9) | 131 (52.4) | |
| Positive | 84 (49.1) | 119 (47.6) | |
| Grading, n (%) | 0.745 | ||
| G1 | 7 (4.1) | 13 (5.1) | |
| G2 | 57 (33.1) | 90 (35.6) | |
| G3 | 108 (62.8) | 150 (59.3) | |
| Ki67 | |||
| Mean ± SD | 32.2 ± 21.4 | 27.7 ± 19.9 | 0.025 |
| ≤15 % | 55 (33.1) | 106 (42.7) | 0.062 |
| >15 % | 111 (66.9) | 142 (57.3) | |
| ER | 0.036 | ||
| Negative | 21 (12.1) | 52 (20.2) | |
| Positive | 152 (87.9) | 206 (79.8) | |
| PgR | 0.026 | ||
| Negative | 25 (14.5) | 60 (23.3) | |
| Positive | 147 (85.5) | 198 (76.7) | |
| HER2 | 0.700 | ||
| Negative | 140 (81.4) | 214 (82.9) | |
| Positive | 32 (18.6) | 44 (17.1) | |
| Treatment, n (%) | 0.016 | ||
| Chemotherapy only | 25 (14.4) | 55 (21.3) | |
| Endocrine therapy only | 38 (22.0) | 75 (29.1) | |
| Chemotherapy followed by endocrine therapy | 110 (63.6) | 128 (49.6) | |
ER estrogen receptor, PgR progesterone receptor